Reuben Benjamin is a Consultant Haematologist and Honorary Senior Lecturer with an interest in multiple myeloma, stem cell transplantation and cell therapy.
He completed his haematology training at University College Hospital, London and then worked as a postdoctorate research fellow at Memorial Sloan Kettering Cancer Center, NY undertaking translational research in CAR-T cell therapy for leukaemia and myeloma.
Since 2014 he has been based at King’s College Hospital, London where he leads the plasma cell disorder service and CAR-T cell programme. He is Chief Investigator of the CALM Trial, the first allogeneic off-the-shelf CAR-T cell study for relapsed adult B-ALL and is also actively involved in offering CAR-T cell therapy for myeloma and lymphoma.
He has an active research group at King’s College London focusing on allogeneic CAR-T cells for lymphoid malignancies as well as in studying the biology of extramedullary myeloma.
